Loading
A phase 2 trial of celecoxib in triple-negative breast cancer, run by Université de Sherbrooke, now recruiting.
Triple Negative Breast Cancer and Celecoxib. Pilot Study is a phase 2, randomised interventional study registered as NCT07104266 by Université de Sherbrooke, with a registry enrolment figure of 30 participants, started 2025-08-04 and due to reach its primary completion in 2028-08-04. Interventions recorded: Celecoxib (Celebrex); Placebo. Conditions listed: Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: "* TNBC status confirmed by pathology". Sites: Canada. No results are recorded here; the registry entry is the source.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.